Manohar K. Raheja bought SGHT once, on Mar 12, 2025

Dr. Manohar K. (MK) Raheja is a seasoned ophthalmology and medical device executive who serves as Executive Vice President, Research & Development at Sight Sciences, Inc. (Nasdaq: SGHT), where he leads global R&D, clinical, and medical affairs activities supporting the company’s surgical glaucoma, sustained drug delivery, and ocular surface disease innovation portfolio.( He was appointed to the EVP, Research & Development role in November 2024 and is a reporting corporate insider of Sight Sciences, including recent Form 4 filings documenting equity transactions in the company’s common stock.(

With more than 35 years of experience in ophthalmic medical device innovation, Dr. Raheja has overseen global organizations responsible for bringing over 70 ophthalmic innovations to market.( His prior corporate leadership roles include Head of Surgical Vision R&D at Johnson & Johnson Vision and Global Head of Corneal & Cataract R&D at Abbott Medical Optics over a 14‑year period ending in 2023, as well as Chief Technology Officer for CIBA Vision (a Novartis company) and President and Chief Operating Officer of Hill Top Research, Inc., a private‑equity‑funded clinical research organization with operations across North America and Europe.( He began his career in R&D at Bausch & Lomb, progressing through multiple leadership positions including Vice President, Research Development & Engineering and Vice President, New Product & New Business Development.( Dr. Raheja holds a Ph.D. from the University of Massachusetts and an Executive M.B.A. from Boston University, and continues to advise emerging ophthalmic companies and nonprofit entrepreneurial institutions alongside his executive responsibilities.(

Written by Perplexity from public sources.